The therapeutic efficacy of orbifloxacin(AT-4526), a new injectable quinolone, on neonatal diarrhea in piglets.:The therapeutic efficacy of orbifloxacin(AT-4526)

概要

論文の詳細を見る
The therapeutic efficacy of orbifloxacin (OBFX), a new injectable quinolone, on neonatal diarrhea in piglets aged 6 to 18 days was clinically evaluated (stool normali-zation) and bacteriologically (change of cell number of Escherichia coli in rectal feces).<BR>Intramuscularly administered OBFX at a dose of 2.5 or 5mg/kg/B. W. for 2-5 days showed a clinical cure rate of 100% in 27 piglets with diarrhea and a bacteriological ef-ficacy rate of 92.6%. The efficacy of OBFX seemed to be unaffected by the co-existence of a rotavirus and/or a transmissible gastroenteritis (TGE) virus, which were detected in the rectal stool of 19 and 11 animals, respectively, by predosing examinations. The susceptibility test of the E. coli, which was isolated in this study (231 strains), revealed that no strain was resistant to OBFX (MIC range:0.05-0.78μg/ml) and what of the strains were resistant (MIC: >100μg/ml) to oxytetracycline, kanamycin and ampicillin. No further clinical side effects were observed.<BR>These results indicated that OBFX is useful antibacterial agent for controlling neonatal diarrhea in piglets.
日本家畜臨床学会の論文